Lexette (halobetasol propionate) foam 0.05% has been made available for patients 18 years of age and older for the topical treatment of plaque psoriasis.
This systematic review was limited by literature that was lacking in survival analyses and inconsistent definitions of drug discontinuation across the literature.
Treatment of psoriasis with biologic therapy is associated with a reduction in noncalcified coronary plaque and improved plaque morphology.
Patients with psoriasis, particularly those with risk factors and severe disease, should receive appropriate screening and preventative intervention.
Compared with foam vehicle, calcipotriol plus betamethasone dipropionate foam offers more rapid and effective itch relief, with associated significant improvements in sleep and Dermatology Life Quality Index scores.
Investigators observed differences and similarities in molecular and histopathologic profiles in skin lesions of patients with psoriasis treated with risankizumab vs ustekinumab.
Methotrexate is well tolerated and effective for psoriasis in a Chinese population and is more effective for those without psoriatic arthritis.
Further research is needed to analyze the mechanisms that are needed for an effective intervention program.
Obesity is an independent risk factor for the development of psoriasis and is associated with a worse prognosis.
In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12.
HLA-C*06:02 status is a predictive biomarker that influences response to adalimumab and ustekinumab in patients with psoriasis.
Desoximetasone with and without phone reminders was associated with clinical improvement in both psoriasis and atopic dermatitis.
Fixed-combination HP/TAZ lotion to manage moderate to severe plaque psoriasis was effective and superior to individual active ingredients.
Investigators noted that itch-related improvements occurred before treatment efficacy was observed using modified PASI scores.
The investigators sought to describe switching patterns in dermatologic real-life daily practice among patients with psoriasis.
An endocrinology consultation should be considered in patients with psoriatic disease who present with thyroid symptoms.
Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.
Considerable numbers of patients with psoriasis and/or psoriatic arthritis in Denmark, Norway, and Sweden are not receiving optimal therapy, according to results of a Scandinavian survey.
Psoriasis is associated with an increased risk for cardiovascular interventions in patients with hypertension.
Depending on the definition used, there are large variations in the proportion of patients identified as having moderate-to-severe psoriasis.
Results showed that HS prevalence was increased in patients with psoriasis when compared with the control participants.
Risk for Adverse Events Same or Lower With Biologics vs Conventional Systemic/Topical Therapies for PsoriasisDecember 31, 2018
Compared with conventional systemic/topical therapies, biologic therapies were associated with similar or lower risk for adverse medical conditions in people with psoriasis.
Patients with moderate to severe plaque psoriasis typically require long-term treatment to achieve disease control.
Using a validated claims-based algorithm, study authors identified pregnancies among women 15-54 years of age from the US Sentinel System between January 1 2004 and September 30 2015.
The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.
During consultation, physicians need to assess the best individual psoriasis treatment option based on the individual patient needs.
In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at weeks 0, 1, 2 3, 4 followed by every 4-week dosing.
The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.
The ability of secukinumab vs placebo to clear nail psoriasis was evaluated using the Nail Psoriasis Severity Index.
Investigators evaluated the effect of ixekizumab withdrawal and retreatment in Japanese patients with plaque psoriasis in this single-arm open-label phase 3 study.
Dermatology Advisor Articles
- Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies
- Strong Bidirectional Association Found Between Depression and Alopecia
- Immunosuppressants Associated With Unsatisfactory Outcomes in Atopic Dermatitis
- Molecular Profiles Vary With Age in Atopic Dermatitis
- Johnson & Johnson to Provide Drug Prices in TV Ads
- Aesthetic-Only Neurotoxin Jeuveau Gets FDA Approval
- Turmeric Polyherbal Supplement May Help Reduce Facial Erythema
- Dupilumab Impacts Symptoms of Atopic Dermatitis in Real-Life Setting
- HIDRAdisk Is a Validated Visual Tool to Assess Hidradenitis Suppurativa Burden
- Thermography Helps Diagnose Allergic vs Irritant Contact Dermatitis